Biointron

06/23/2026

👏 Congratulations to China Medical System Holdings Limited for the approval of silevimig, a bispecific antibody for passive immunization against rabies!

China’s NMPA has approved the novel drug silevimig, the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus. It demonstrates broad neutralization, which can effectively neutralize different viral strains or genotypes of RABV, providing immediate protection.

Silevimig works by targeting the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and III. Through this mechanism, silevimig specifically neutralizes the RABV prior to the establishment of full protection by active rabies vaccination.

Read the press release here 👉 https://www.globenewswire.com/news-release/2026/06/22/3315186/0/en/cms-class-1-innovative-drug-silevimig-injection-approved-in-china-becoming-the-world-s-first-bispecific-antibody-for-passive-immunization-against-rabies.html

SHENZHEN, CHINA, June 22, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce...

06/16/2026

NEW: Introducing RushData 🚀
𝗕𝗶𝗼𝗶𝗻𝘁𝗿𝗼𝗻’𝘀 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗱𝗮𝘁𝗮-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗳𝗼𝗿 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗱𝗲𝘀𝗶𝗴𝗻.

RushData combines high-throughput CHO expression, binding analytics, and early developability profiling to generate structured, actionable datasets for antibody discovery and optimization, in days, not weeks!

• 1-day CHO expression for rapid, standardized data generation
• Parallel processing of 3,000+ molecules per batch
• Custom workflows for different targets and antibody modalities
• Early developability assessments to identify potential liabilities sooner

Choose the service level that fits your program:

𝗕𝗮𝘀𝗶𝗰 – 𝗥𝗮𝗽𝗶𝗱 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴
Expression, titer, and affinity

𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱 – 𝗕𝗶𝗻𝗱𝗶𝗻𝗴 𝗖𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻
Expression, concentration, cGE, and affinity

𝗣𝗿𝗲𝗺𝗶𝘂𝗺 – 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗣𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴
Binding characterization plus early developability assessments

Learn more 👉 https://www.biointron.com/rushdata

06/16/2026

𝗛𝗼𝘄 𝗰𝗮𝗻 𝗺𝗮𝗰𝗵𝗶𝗻𝗲 𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝗵𝗲𝗹𝗽 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗲 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗽𝗿𝗼𝗽𝗲𝗿𝘁𝗶𝗲𝘀 𝗮𝘁 𝗼𝗻𝗰𝗲? 🤖

A recent review by University of Michigan researchers examines the growing role of AI and machine learning in multi-objective antibody design and optimization.

Besides antibody affinity, successful antibody development involves balancing multiple properties like specificity, stability, aggregation, polyreactivity, immunogenicity, and developability. Optimizing one parameter can hinder the development of another, making the identification of clinically suitable candidates a time-consuming process.

The review highlights emerging approaches such as:
• AI/ML-guided co-optimization across multiple antibody properties
• Deep sequencing and antibody sub-libraries for broader sequence-space exploration
• Computational prediction of co-optimal variants without sub-library generation
• Energy-based and interpretable ML models for humanization and developability optimization
• Proof-of-concept strategies for de novo antibody design

Find the paper here 👉 https://www.nature.com/articles/s44222-026-00444-4

Antibodies are among the best-selling drugs and are crucial for numerous therapeutic and diagnostic purposes. However, optimizing antibodies for desirable drug-like properties has long been a hurdle, delaying or preventing promising drugs from reaching patients. Advances in computational methods, es...

06/08/2026

𝗪𝗵𝗮𝘁 𝗶𝗳 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗰𝗼𝘂𝗹𝗱 𝗯𝗲 𝘁𝘂𝗿𝗻𝗲𝗱 𝗢𝗡 𝗮𝗻𝗱 𝗢𝗙𝗙? 💡

A new study from KAIST researchers introduces “extrabody”, an optogenetic, stimulus-gated antibody platform that brings spatiotemporal control to antigen recognition.

Extrabody is based on split antibody fragments (derived from nanobody or scFv) that remain inactive until triggered. Upon blue light or small-molecule inducers, the fragments reassemble, enabling inducible extracellular antigen recognition.

At Biointron, we’re excited to see how innovations like this push antibody discovery toward more dynamic, data-driven design.

Read the full paper here 👉 https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(26)00141-8

Precise control of antigen recognition remains a challenge in engineering cell-cell interactions. Kwon et al. develop extrabody, a split antibody platform that enables optogenetic and chemical control of extracellular antigen binding, allowing inducible cell-cell communication and programmable immun...

06/05/2026

🚀 𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: 𝗕𝗶𝗼𝗶𝗻𝘁𝗿𝗼𝗻 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗥𝘂𝘀𝗵𝗠𝗮𝗯™ 𝗣𝗮𝗰𝗸𝗮𝗴𝗲𝘀 𝘁𝗼 𝗗𝗲𝗹𝗶𝘃𝗲𝗿 𝗣𝘂𝗿𝗶𝗳𝗶𝗲𝗱 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗶𝗻 𝟭𝟬 𝗗𝗮𝘆𝘀

RushMab™ compresses the wait for antibody expression! 4 days for transfection-grade expression plasmids, and 10 days for purified, quality-controlled antibodies.

• RushMab™ - Gene: 100ug transfection grade expression plasmids
• RushMab™ - Super (24/96-well plate): 1ml supernatant, expression plasmids
• RushMab™ - Mini: ≥100ug purified antibody, expression plasmids
• RushMab™ - Standard: ≥1mg purified antibody, expression plasmids

Take a look at the press release here https://finance.yahoo.com/sectors/healthcare/articles/biointron-launches-rushmab-packages-deliver-151200469.html

CAMBRIDGE, MA, May 29, 2026 (GLOBE NEWSWIRE) -- CAMBRIDGE, MA - May 29, 2026 - - Biointron, a Shanghai-based antibody contract research organization with offices in Cambridge, MA and Piscataway, NJ, has introduced RushMab™, a suite of small-scale antibody expression packages that deliver purified ...

06/04/2026

𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗼𝗻 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗔𝗗𝗖𝘀 𝗳𝗿𝗼𝗺 𝗕𝗶𝗼𝗶𝗻𝘁𝗿𝗼𝗻 𝗠𝗼𝗻𝘁𝗵𝗹𝘆:

🔬 BsADCs are being engineered to improve internalization and payload delivery
🔎 Dual targeting is being used to address tumor heterogeneity and target escape
🧪 BsADC development in the lens of manufacturability and stability

https://www.linkedin.com/pulse/antibody-industry-trends-june-2026-bispecific-adcs-dual-targeted-0g4he/

As part of our regular updates, we bring you the Monthly Recap this week, spotlighting what you need to know in June. Introduction Antibody-drug conjugates, or ADCs, have become an important class of targeted cancer therapeutics because they combine the binding specificity of antibodies with the cyt

06/03/2026

Roundup of deals in May 2026 👇

🤝 Pfizer and Innovent Biologics strike $10.5B deal to collaborate on development of up to 12 antibody drugs (ADCs & multispecifics). https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-innovent-biologics-enter-global-strategic

🤝 Regeneron and Parabilis Medicines collaborate to advance novel antibody-helicon conjugates across multiple therapeutic areas in $2.3B deal. https://parabilismed.com/press-release/parabilis-medicines-announces-strategic-collaboration-with-regeneron-pharmaceuticals-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas/

🌱 Protuoso Biosciences raises $9.5M seed financing for hub-and-spoke platform to advance multifunctional Muxbodies (fully recombinant fusion proteins). https://www.protuoso.bio/post/exclusive-protuoso-gets-9-5m-to-build-the-next-hub-and-spoke-antibody-developer

💰 InMed Pharmaceuticals & Mentari Therapeutics to merge, advancing migraine prevention antibody therapies in $290M deal.
https://www.inmedpharma.com/news_release/inmed-pharmaceuticals-mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies/

🤝 Bristol Myers Squibb and Hengrui Pharma enter collaboration worth $15.2B in 13-asset deal (oncology, hematology, immunology). https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-and-Hengrui-Pharma-Announce-Strategic-Agreements-to-Advance-Innovative-Medicines-Across-Oncology-Hematology-and-Immunology-2026-EbQpaI6Zdc/default.aspx

💸 Infex Therapeutics secures £4.3M funding to advance anti-infective pipeline targeting drug-resistant infections, with lead program RESP-X, a monoclonal antibody. https://www.infextx.com/infex-therapeutics-secures-4-3-million-funding-to-advance-anti-infective-pipeline-targeting-drug-resistant-infections/

💸 Cytospire Therapeutics raises £61M ($83M) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer. https://www.cytospire.com/cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell-engagers-into-clinical-trials-for-the-treatment-of-can/

💰 UCB Biopharma to acquire Candid Therapeutics for $2.2B for T-cell engagers in autoimmunity; lead asset cizutamig is an anti-BCMA/anti-CD3 bispecific antibody. https://www.ucb.com/newsroom/press-releases/article/ucb-to-acquire-candid-therapeutics-building-upon-its-existing-immunology-pipeline-with-novel-t-cell-engagers

💸 Windward Bio gets $165M crossover financing to advance two clinical-stage antibodies as long-acting immunology therapies. https://www.globenewswire.com/news-release/2026/05/04/3286605/0/en/windward-bio-announces-165m-crossover-financing-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential.html

💰 Liminatus pays $320M to merge with InnocsAI, combining CAR-T and antibody-related technologies. https://www.biospace.com/press-releases/liminatus-pharma-announces-proposed-merger-with-innocsai-to-expand-oncology-cell-therapy-pipeline

💵 Boehringer Ingelheim licenses preclinical antibody from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases in €407.5M deal. https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-licenses-immunitas-novel-antibody-program

💸 LTZ Therapeutics raises $38M to advance myeloid engager immunotherapy pipeline, incl. lead asset LTZ-301, a novel myeloid engager bi-specific antibody that depletes CD79b+ B-cells. https://www.ltztherapeutics.com/html/news/139.html

💵 Context Therapeutics to pay $6.5M to BioAtla, Inc. for full rights to CT-202 (a Nectin-4 x CD3 TCE bispecific). https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-enters-license-agreement-amendment-bioatla

💸 Apogee Therapeutics announces $1.3B financing collaboration with Blackstone Life Sciences to advance phase 3 development of zumilokibart, an anti-IL-13 mAb for AD. https://www.blackstone.com/news/press/apogee-therapeutics-announces-1-3-billion-strategic-financing-collaboration-with-blackstone-life-sciences-to-advance-phase-3-development-and-commercialization-of-zumilokibart/

🤝 Delos Capital and AP Biosciences Inc. launch collaboration to create new biotech companies focused on autoimmune diseases using bi- and tri-specific antibodies. https://www.biospace.com/press-releases/delos-capital-and-ap-biosciences-inc-launch-collaboration-to-create-new-biotech-companies-focused-on-next-generation-antibodies

💵 Whitehawk Therapeutics expands ADC pipeline with optiosn for up to five ADC Programs, including dual-payload variations from Hangzhou DAC. https://ir.whitehawktx.com/news-releases/news-release-details/whitehawk-therapeutics-expands-adc-pipeline-new-option-agreement

06/01/2026

🧬 𝗖𝗮𝗻 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗯𝗲 𝘂𝘀𝗲𝗱 𝘁𝗼 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝘁𝘂𝗿𝗻 𝗱𝗼𝘄𝗻 𝗧 𝗰𝗲𝗹𝗹 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲𝘀?

A new study led by The University of Osaka introduces immune-induced TCR-like antibodies (iTabs), and their potential role in controlling antigen-specific immunity.

During normal immune responses, the body can generate antibodies that recognize peptide–MHC class II complexes, much like T cell receptors (TCRs) do. These iTabs can:
• Block TCR recognition of antigen-presenting MHC-II
• Selectively suppress antigen-specific CD4⁺ T cell responses
• Reduce autoimmune disease progression in a mouse model

This opens up a potential new strategy for precision immune modulation: using specifically designed peptides to lower harmful immune responses without broadly suppressing immunity.

Read the paper here https://www.nature.com/articles/s41467-026-71384-1

Here, the authors investigate whether antibodies specific to the antigen peptide-MHC class II complex are generated during the immune response and whether these antibodies can limit hyperimmune responses. They identify a class of antibodies, called iTabs, that recognize peptide-MHC class II complexe...

05/29/2026

𝐎𝐧𝐥𝐲 𝟏 𝐰𝐞𝐞𝐤 𝐭𝐢𝐥𝐥 𝐭𝐡𝐞 𝟑𝟏𝐬𝐭 𝐂𝐁𝐀 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞!
Join us for a conversation on advances in antibody research. We look forward to connecting with you in Gaithersburg!

📅 Date: June 06, 2026
📍 Location: Marriott Washingtonian Center | Gaithersburg, MD

Register for a 1-on-1 time with us here:
🔗 https://www.surveymonkey.com/r/CQH9TSX

05/27/2026

🎉 Congratulations to our Q2 2026 Travel Grant Winner!

We are excited to announce that Siyu Sun, PhD, Postdoctoral Researcher at Synapse Research Institute, has been selected as Biointron’s Q2 2026 Travel Grant recipient!

📍 Dr. Sun will be presenting at ISTH Congress (July 11–15, 2026), on: Targeting fibrin fiber lateral expansion remodels clot mechanics, contraction and fibrin-dependent thrombin protection

Dr. Sun’s research centers on thrombin, platelets, and fibrin in blood clot formation. She contributes to the development of novel antibody-based therapeutic strategies for thrombotic and bleeding disorders, and is involved in the development of a new high-throughput method to asses thrombin generation to redefine the blood cell contributions to the clotting process.

👉 Interested in attending a conference with support from Biointron? Apply for our travel grant program here: https://www.biointron.com/promotions/travel-grant-program.html

Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.